Resolution No. 10/04-2

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

VACCINES FOR CHILDREN PROGRAM

INFLUENZA

VACCINES TO PREVENT INFLUENZA

The purpose of this resolution is to revise the previous resolution to clarify risk groups, incorporate the use of live attenuated influenza vaccine and to update the recommendation for the use of inactivated influenza vaccine in pregnant women.

VFC resolution 6/02-1 is repealed and replaced by the following:

Eligible Groups for Inactivated Influenza Vaccine

Children aged 6 months through 23 months.

Children and adolescents aged 2 through 18 years with chronic disorders of the pulmonary or cardiovascular systems, including asthma.

Children and adolescents aged 2 through 18 years who have required regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus [HIV]).

Children and adolescents aged 2 through 18 years who are receiving long-term aspirin therapy and may therefore be at risk for developing Reye syndrome after influenza.

Children and adolescents aged 2 through 18 years who are residents of nursing homes and other chronic-care facilities that house persons at any age who have chronic medical conditions.

Adolescent females aged <19 years who will be pregnant during influenza season.

Children and adolescents aged 2 through 18 years who are household contacts or out-of-home caregivers of persons in the following high-risk groups:

1. children less than 2 years old;
2. adults aged 50 years or older;
3. persons with chronic disorders of the pulmonary or cardiovascular systems, including asthma;
4. persons who have required regular medical follow-up or hospitalization during the preceding year for chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus [HIV]);

5. children and adolescents aged 2 through 18 years who are receiving long-term aspirin therapy and may therefore be at risk for developing Reye syndrome after influenza;
6. residents of nursing homes and other chronic-care facilities that house persons at any age who have chronic medical conditions;
7. women who will be pregnant during influenza season.

Eligible Groups for Live Attenuated Influenza Vaccine (LAIV)

Healthy children and adolescents aged 5 years through 18 years who are household contacts or out-of-home caregivers of persons in the following high-risk groups provided that the contacts are not severely immunocompromised (e.g., patients with hematopoietic stem cell transplants) and requiring care in a protective environment:

1. children less than 2 years old;
2. adults aged 50 years or older;
3. persons with chronic disorders of the pulmonary or cardiovascular systems, including asthma;
4. persons who have required regular medical follow-up or hospitalization during the preceding year for chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus [HIV]);
5. children and adolescents aged 2 through 18 years who are receiving long-term aspirin therapy and may therefore be at risk for developing Reye syndrome after influenza;
6. residents of nursing homes and other chronic-care facilities that house persons at any age who have chronic medical conditions;
7. women who will be pregnant during influenza season.

Recommended Influenza Vaccine Schedule

Age Group*	Number of doses
6 months - 8 years	1 or 2¶
>8 years	1

* Fluvirin® purified surface antigen vaccine (Chiron Corporation) is approved for use only among persons aged ≥4 years. FluMist™ live, attenuated influenza vaccine (MedImmune Vaccines, Inc.) is approved for use only among healthy persons aged 5-49 years.

¶ Two doses are recommended for children <9 years of age who are receiving influenza vaccine for the first time.

NOTE: Use of brand names is not meant to preclude the use of other licensed influenza vaccines.

Recommended Dosage Intervals

Vaccine	Minimum Age*	Minimum interval dose 1 to 2 (where applicable) ¶
Influenza, inactivated	6 months	28 days
Influenza, live attenuated	5 years	42 days

* Fluvirin® purified surface antigen vaccine (Chiron Corporation) is approved for use only among persons aged ≥4 years. FluMist™ live, attenuated influenza vaccine (MedImmune Vaccines, Inc.) is approved for use only among healthy persons aged 5-49 years.

¶ Two doses are recommended for children <9 years of age who are receiving influenza vaccine for the first time.

Recommended Dosages

Refer to product package inserts.

Contraindications and Precautions

The following conditions are contraindications to administration of influenza vaccine:

1. Allergy to vaccine components
   Anaphylactic reaction to the vaccine or a constituent of the vaccine (e.g. eggs).

2. Moderate or severe illnesses with or without fever
   Persons with moderate or severe illness should be immunized as soon as they have recovered from the acute phase of the illness. Minor illnesses (e.g., upper respiratory tract infection, allergic rhinitis) with or without fever should not contraindicate the use of influenza vaccine (either inactivated or live, attenuated vaccine).

3. The following children and adolescents should not be vaccinated with LAIV:

   - children aged <5 years;
   - persons with asthma, reactive airways disease or other chronic disorders of the pulmonary or cardiovascular systems; persons with other underlying medical conditions, such as the metabolic diseases diabetes, renal dysfunction, and hemoglobinopathies; or persons with known or suspected immunodeficiency diseases or who are receiving immunosuppressive therapies;
   - children or adolescents receiving aspirin or other salicylates (because of the association of Reye syndrome with wild-type influenza infection);
   - persons with a history of GBS;
   - pregnant women; or
   - persons with a history of hypersensitivity, including anaphylaxis, to any of the components of LAIV or to eggs.

The following condition is a precaution to receipt of influenza inactivated virus vaccine:

1. History of Guillain-Barré Syndrome within 6 weeks following influenza vaccination.

Adopted: October 28, 2004
Effective: July 1, 2005 for vaccine to be administered in the 2005-06 and subsequent influenza vaccination seasons.